With $120m, HI-Bio Aims To Rapidly Prove Approach To Immune-Mediated Diseases

Phase Ib/IIa Trials To Read Out Next Year

 
• By Mandy Jackson

Human Immunology Biosciences (HI-Bio) launched with $120m and two candidates from MorphoSys, including the CD38 inhibitor felzartamab already in the clinic for immune-mediated kidney diseases.

Venture capital or financial support for startup and entrepreneur company
HI-Bio connected with new investor Jeito in its latest financing • Source: Shutterstock

More from Financing

More from Business